PMV Pharmaceuticals (PMVP) Registration Filing summary

Company overview and business model

• Precision oncology company focused on developing small molecule, tumor-agnostic therapies targeting p53 mutations, which are present in about half of all cancers.

• Lead candidate, PC14586 (rezatapopt), targets the p53 Y220C mutation and is in a pivotal Phase 2 trial, with global site activation and interim data expected by mid-2025.

• Pursuing a tumor-agnostic development strategy and collaborating with major cancer centers for additional studies.

• Granted FDA Fast Track Designation for PC14586 and aims for accelerated approval pathways.

Financial performance and metrics

• As of November 19, 2024, the last reported sale price of common stock was $1.59 per share.

• 51,749,504 shares outstanding as of September 30, 2024, with potential for up to 123,317,331 shares post-offering depending on sale price and volume.

• Previously raised approximately $35.1 million through at-the-market offerings at a weighted average price of $6.97 per share.

Use of proceeds and capital allocation

• Net proceeds will be used for general corporate purposes, including clinical trial and R&D expenses, commercialization, capital expenditures, working capital, and potential acquisitions or investments.

• Pending use, proceeds will be invested in short- and intermediate-term, interest-bearing obligations and investment-grade instruments.